• SCS Microinjector® features
  • Methods of using SCS Microinjector for drug delivery

  • Device using an adjustable needle


  • Administration of a variety of drugs to the suprachoroidal space by microinjection

  • Administration of a variety of drugs to the eye by inserting a microinjector into the sclera


  • Methods of treating posterior ocular disorders by SCS administration

Intellectual Property Overview

  1. Comprehensive IP portfolio that includes protection of: SCS delivery technology, proprietary SCS Microinjector, treatment of various conditions with SCS administration of therapeutic products
  2. Multiple U.S., European and International issued patents with additional pending patent applications
  3. Granted patents provide exclusivity for our delivery technology and product candidates to mid-2030s with pending applications potentially extending exclusivity beyond 2040
  4. At least the following U.S. patents apply to the products listed below. This page is intended to serve as notice under 35 U.S.C. § 287(a).

XIPERE® (triamcinolone acetonide injectable suspension), for suprachoroidal use

  • US 8,197,435
  • US 9,539,139
  • US 9,937,075
  • US 10,555,833
  • US 10,390,901
  • Other patents pending